Poriferast-5-en-3β-ol improves pelvic inflammatory disease via reducing GADD45A-induced inflammation

Key Points

• Reduction of inflammation significantly improves pelvic inflammatory disease outcomes and GADD45A levels.
• GADD45A levels dropped by a notable percentage, pinpointing the efficacy of poriferast-5-en-3β-ol.
• This analysis focuses on inflammation pathways impacted by poriferast-5-en-3β-ol in pelvic inflammatory disease.
• Future clinical strategies may harness poriferast-5-en-3β-ol for managing pelvic inflammatory disease resolution.